Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The CDC estimates that 21% of people living with HIV also have hepatitis C virus.
People treated with Biktarvy were more likely to achieve an undetectable HBV viral load than those on a dolutegravir-based regimen.
The burden of viral and nonviral liver disease remains high even in the setting of hepatitis C microelimination.
People who are living with all three viruses have a greater likelihood of progressing to end-stage liver disease.
Women who had both hepatitis C and HIV were most likely to pass HCV on to their newborns.
Cutting the duration of treatment also cut the likelihood of a cure.
People with both HIV and hepatitis C are at greater risk for myocardial infarction as they age, and traditional risk factors also matter.
The risk of HCC fell further as cumulative antihistamine use rose in people with HBV, HCV or both.
Held in person and virtually, AIDS 2022 is the world’s largest HIV-related gathering. From cure news to advocacy, here’s what to expect.
However, some 10% experienced liver decompensation even after antiviral therapy.
Suppression of hepatitis B virus with antiviral treatment lowered the risk of hepatocellular carcinoma by 58%.
There are a variety of hepatitis C treatments offered for all genotypes, with various stages of liver damage.
Increased HCV testing and treatment for both HIV-positive and HIV-negative gay and bi men could help eliminate hep C.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.